---
title: "HeartSciences Inc. (HSCS.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/HSCS.US.md"
symbol: "HSCS.US"
name: "HeartSciences Inc."
industry: "Health Care Equipment"
---

# HeartSciences Inc. (HSCS.US)

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Location | US Market |
| Website | [eartsciences.com](https://eartsciences.com) |

## Company Profile

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunctio...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:11.000Z

**Overall: D (0.73)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 142 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -41.03% |  |
| Net Profit YoY | -18.52% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.28 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9.54M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 8669.00 |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -220.46% | E |
| Profit Margin | -104237.92% | E |
| Gross Margin | 58.33% | B |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -41.03% | E |
| Net Profit YoY | -18.52% | D |
| Total Assets YoY | -22.90% | E |
| Net Assets YoY | 4.13% | C |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.10% | D |
| OCF YoY | -41.03% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 30.25% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - HeartSciences Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-220.46%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-104237.92%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "58.33%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-41.03%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-18.52%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-22.90%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.13%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.10%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-41.03%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "30.25%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Inspire Medical (US.INSP) | A | B | A | A | B | A |
| 02 | Delcath (US.DCTH) | C | A | A | A | A | A |
| 03 | Intuitive Surgical (US.ISRG) | A | B | C | A | B | B |
| 04 | Stryker (US.SYK) | A | B | C | C | B | B |
| 05 | Boston Scientific (US.BSX) | B | B | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.06 | 82/181 | - | - | - |
| PB | 2.28 | 59/181 | 3.14 | 2.41 | 2.00 |
| PS (TTM) | 1100.48 | 147/181 | 1529.32 | 1110.85 | 203.07 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-21T05:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 50% |
| Overweight | 1 | 50% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.00 |
| Highest Target | 12.00 |
| Lowest Target | 9.20 |

## References

- [Company Overview](https://longbridge.com/en/quote/HSCS.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/HSCS.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/HSCS.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.